# Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

> **NCT02100514** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 746 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Bococizumab (PF-04950615; RN316)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02100514
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2016-07-15
- **Final completion:** 2017-07-10
- **Target enrollment:** 746 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100514, "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02100514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*